Tumor Associated Fibroblasts Promote HER2-Targeted Therapy Resistance through FGFR2 Activation.

CONCLUSIONS: We have identified the TAF/FGF5/FGFR2/c-Src/HER2 axis as an escape pathway responsible for HER2 targeted therapies resistance in breast cancer which can be reversed by FGFR inhibitors.
PMID: 31699826 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - November 6, 2019 Category: Cancer & Oncology Authors: Fernandez-Nogueira P, Mancino M, Fuster G, Lopez-Plana A, Jauregui P, Almendro V, Enreig E, Menéndez S, Rojo F, Noguera-Castells A, Bill A, Gaither LA, Serrano L, Recalde-Percaz L, Moragas N, Alonso R, Ametller E, Rovira A, Lluch A, Albanell J, Gascon P, Tags: Clin Cancer Res Source Type: research